Case Reports in Dermatology最新文献

Erratum. 勘误表。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-04-08 eCollection Date: 2026-01-01 DOI: 10.1159/000551340

引用次数: 0

Erratum. 勘误表。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-04-08 eCollection Date: 2026-01-01 DOI: 10.1159/000551341

引用次数: 0

Scanning Acoustic Microscopy as a Novel Quantitative Tool for Assessing Dermal Sclerosis in Systemic Sclerosis: A Case Report. 扫描声学显微镜作为评估系统性硬化症中皮肤硬化的一种新的定量工具：一个病例报告。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-03-20 eCollection Date: 2026-01-01 DOI: 10.1159/000550671

Kyoko Kanno, Satomi Igawa, Masaru Honma, Yuki Ogura, Tomonobu Ezure, Akemi Ishida-Yamamoto

{"title":"Scanning Acoustic Microscopy as a Novel Quantitative Tool for Assessing Dermal Sclerosis in Systemic Sclerosis: A Case Report.","authors":"Kyoko Kanno, Satomi Igawa, Masaru Honma, Yuki Ogura, Tomonobu Ezure, Akemi Ishida-Yamamoto","doi":"10.1159/000550671","DOIUrl":"https://doi.org/10.1159/000550671","url":null,"abstract":"Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by skin fibrosis and internal organ involvement. Quantitative methods for assessing skin sclerosis beyond the modified Rodnan skin score (mRSS) are required to better monitor disease progression and treatment response.Case presentation: A 61-year-old woman with rapidly progressing SSc and early interstitial lung disease was treated with IVCY. Skin biopsies were obtained before and after treatment. Scanning acoustic microscopy (SAM) was used to measure the speed of sound within the skin tissue, reflecting tissue stiffness. A histological analysis was performed. Following IVCY, SAM significantly decrease the speed of sound within the affected skin tissue, preceding a measurable reduction in mRSS. Histological analysis showed improvements in collagen bundle architecture and reduced inflammatory cell infiltration.Conclusion: SAM may be a promising, objective, and quantitative technique for evaluating skin sclerosis in patients with SSc and for monitoring early therapeutic responses. This is an exploratory observation based on a single case. Further investigations in larger, controlled clinical trials are warranted to determine its clinical utility and predictive value.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"215-221"},"PeriodicalIF":0.8,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adalimumab and Tofacitinib Combination Therapy for Pyoderma Gangrenosum: A Case Report. 阿达木单抗与托法替尼联合治疗坏疽性脓皮病1例。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-03-06 eCollection Date: 2026-01-01 DOI: 10.1159/000550618

Jingjing Yang, Shunlong Zhou, Chao Liu

{"title":"Adalimumab and Tofacitinib Combination Therapy for Pyoderma Gangrenosum: A Case Report.","authors":"Jingjing Yang, Shunlong Zhou, Chao Liu","doi":"10.1159/000550618","DOIUrl":"https://doi.org/10.1159/000550618","url":null,"abstract":"Introduction: Pyoderma gangrenosum (PG) is a rare inflammatory skin disease causing progressive necrotizing ulcers with limited treatment options due to adverse effects and high recurrence rates.Case presentation: We present a case of a 70-year-old elderly patient diagnosed as PG, which was unresponsive to initial prednisolone treatment. After approximately 3 weeks of an individualized treatment regimen of adalimumab combined with tofacitinib, disease progression was halted, accompanied by a significant reduction in ulcer size, reduced exudation, and substantial pain relief. Subsequent tapering and discontinuation of prednisolone, followed by 6 weeks of combined adalimumab and tofacitinib and 8 weeks of tofacitinib monotherapy, resulted in complete ulcer healing by week 17. No recurrence of inflammatory activity was observed during the follow-up period of over 7 months.Conclusion: This case highlights the successful and rapid efficacy of adalimumab and tofacitinib combination therapy for PG, offering a novel strategic reference for individualized treatment, particularly in recurrent or cases unresponsive to initial treatment.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"177-181"},"PeriodicalIF":0.8,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stevens-Johnson Syndrome following a Single Ampicillin Dose in an Elderly Patient: A Case Report. 老年患者单次氨苄西林后史蒂文斯-约翰逊综合征1例报告。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-02-27 eCollection Date: 2026-01-01 DOI: 10.1159/000550570

A'sem Mohammad Abedalqader Qannas, Syed Iftiqar Ahmed, Ketevan Machavariani, Nabil Tariq, Rana Hussain Abdul Rehman, Nino Abuladze, Ahmed Abdelkader

{"title":"Stevens-Johnson Syndrome following a Single Ampicillin Dose in an Elderly Patient: A Case Report.","authors":"A'sem Mohammad Abedalqader Qannas, Syed Iftiqar Ahmed, Ketevan Machavariani, Nabil Tariq, Rana Hussain Abdul Rehman, Nino Abuladze, Ahmed Abdelkader","doi":"10.1159/000550570","DOIUrl":"https://doi.org/10.1159/000550570","url":null,"abstract":"Introduction: Stevens-Johnson syndrome (SJS) is a rare but life-threatening mucocutaneous disorder, most commonly triggered by medications.Case presentation: We present the case of a 75-year-old Armenian female who developed severe SJS following a single dose of ampicillin. She initially presented with fever, generalized weakness, and a rapidly progressing bullous rash affecting her face, neck, upper limbs, and chest. Her medical history included untreated rheumatoid arthritis and chronic bronchitis, for which she had been self-medicating with corticosteroids and other medications. Despite early initiation of high-dose corticosteroids and supportive therapy, her condition deteriorated, leading to septicemia and respiratory failure, necessitating admission to the Infectious Diseases Department. Multidisciplinary management, including immunosuppressive therapy with cyclosporine and targeted antimicrobial treatment, resulted in clinical stabilization and eventual recovery.Conclusion: This case highlights that even minimal exposure to beta-lactam antibiotics can precipitate severe SJS in elderly and immunocompromised patients. Early recognition and prompt multidisciplinary intervention are essential to improve outcomes.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"184-191"},"PeriodicalIF":0.8,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ocular Manifestations Leading to the Diagnosis of Pseudoxanthoma Elasticum with a Novel Heterozygous ABCC6 Mutation: A Case Report. 具有新型杂合ABCC6突变的弹性假黄瘤的眼部表现：1例报告。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-02-27 eCollection Date: 2026-01-01 DOI: 10.1159/000550862

Akihiro Fukuta, Yohei Iwata, Rena Yasuda, Akira Iwanaga, Hiroyuki Murota, Kazumitsu Sugiura

{"title":"Ocular Manifestations Leading to the Diagnosis of Pseudoxanthoma Elasticum with a Novel Heterozygous ABCC6 Mutation: A Case Report.","authors":"Akihiro Fukuta, Yohei Iwata, Rena Yasuda, Akira Iwanaga, Hiroyuki Murota, Kazumitsu Sugiura","doi":"10.1159/000550862","DOIUrl":"https://doi.org/10.1159/000550862","url":null,"abstract":"Introduction: Pseudoxanthoma elasticum (PXE) is a progressive hereditary disease caused by the calcification and degeneration of elastic fibers, affecting the skin, retina, blood vessels, and gastrointestinal tracts. The gene responsible is the ATP-binding cassette subfamily C member 6 (ABCC6).Case presentation: A 47-year-old man presented to an ophthalmologist with a right eyelid contusion. Fundus examination revealed right macular hemorrhage and bilateral angioid streaks. PXE was suspected due to skin lesions around the neck and abdomen; he was referred to our dermatology department. Histopathological examination revealed degenerated anucleate elastic fibers with calcification in the mid-dermis. Genetic testing revealed a previously unreported heterozygous ABCC6 mutation. We established a diagnosis of PXE based on characteristic skin lesions and histopathological findings triggered by ocular manifestations. Based on in silico analysis, the ABCC6 gene mutation was predicted to be pathogenic.Conclusion: In some PXE cases, the ABCC6 gene mutation can be undetectable or only one mutation is detected; PXE could be diagnosed based on clinical and histopathological symptoms. When characteristic skin and eye lesions are observed, appropriate evaluation is required. Genetic testing facilitates early diagnosis and the discovery of novel mutations, contributing to a deeper understanding of the disease spectrum.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"192-198"},"PeriodicalIF":0.8,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13075883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Ectopic Hidradenitis Suppurativa of the Lower Leg with Setons: A Case Report. 塞通治疗下肢化脓性异位汗腺炎1例。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-02-17 eCollection Date: 2026-01-01 DOI: 10.1159/000551053

Minna Möller, Anja Pahlow Mose, Meirav Holmdahl

引用次数: 0

Kaposi Sarcoma Associated with Pemphigus Vulgaris in the Setting of Immunosuppressive Therapy: Case Report and Review of Literature. 免疫抑制治疗下卡波济肉瘤合并寻常性天疱疮的病例报告及文献复习。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-02-14 eCollection Date: 2026-01-01 DOI: 10.1159/000551054

Hanie Masouri, Sepehr Broumand Sani, Sama Heidari, Navid Namakizadeh Esfahani

{"title":"Kaposi Sarcoma Associated with Pemphigus Vulgaris in the Setting of Immunosuppressive Therapy: Case Report and Review of Literature.","authors":"Hanie Masouri, Sepehr Broumand Sani, Sama Heidari, Navid Namakizadeh Esfahani","doi":"10.1159/000551054","DOIUrl":"https://doi.org/10.1159/000551054","url":null,"abstract":"Introduction: Pemphigus vulgaris (PV) is a chronic autoimmune blistering disorder characterized by intraepidermal blisters affecting the skin and mucous membranes. The primary treatment for PV is systemic corticosteroid therapy, which is often prolonged due to the disease's chronic and relapsing course. The interplay between autoimmunity and long-term immunosuppressive treatment can predispose patients to secondary complications, including Kaposi sarcoma (KS), an angioproliferative tumor primarily involving the skin and soft tissues. When KS develops in the context of immunosuppressive therapy, particularly in patients with autoimmune diseases such as PV, it is classified as iatrogenic KS.Case presentation: We report the case of a 74-year-old female diagnosed with PV who developed iatrogenic KS following treatment with high-dose intravenous immunoglobulin (150 g) and systemic corticosteroids. Despite tapering of immunosuppressive medications, the KS lesions did not regress. As a result, the patient was referred to an oncologist for further evaluation and management.Conclusion: This case highlights the potential role of both autoimmunity and immunosuppressive therapy in the development of iatrogenic KS. While tapering immunosuppressive drugs has been reported as an effective approach for KS resolution in some cases, it may not be sufficient in all instances. Close monitoring and timely oncologic referral are essential in managing such complications.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"199-209"},"PeriodicalIF":0.8,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13075888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report. 5- α还原酶抑制剂治疗患者药物性黄褐斑1例。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-02-14 eCollection Date: 2026-01-01 DOI: 10.1159/000551051

Hiba Elhaj, Kelsey A Orrell, Renée A Beach

{"title":"Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report.","authors":"Hiba Elhaj, Kelsey A Orrell, Renée A Beach","doi":"10.1159/000551051","DOIUrl":"10.1159/000551051","url":null,"abstract":"Introduction: Melasma is a chronic hyperpigmentation disorder with pathogenesis linked to hormonal mediation, ultraviolet and heat exposure, and genetic predisposition. Five-alpha reductase inhibitors (5-ARIs), including finasteride and dutasteride, are widely prescribed for treatment of benign prostatic hyperplasia (BPH) and off-label for androgen-mediated dermatologic conditions, yet pigmentary adverse effects are rarely reported. To date, only one case documenting melasma following 5-ARI use has been published. We report two additional cases of finasteride-induced melasma.Case summaries: A 53-year-old woman with Fitzpatrick Skin Type V developed progressive cheek hyperpigmentation approximately 1 year after initiating oral finasteride for frontal fibrosing alopecia. Clinical evaluation supported a diagnosis of melasma. Finasteride was discontinued, and treatment with cysteamine 5% cream led to partial improvement within 5 months. A 66-year-old man with FST VI presented with 1 year history of melasma on his forehead and temples, unresponsive to multiple topical therapies. It was revealed he had been taking oral finasteride for approximately 10 years for treatment of BPH. He was diagnosed with 5-ARI-induced melasma. Therapy was modified to include cysteamine cream, glutathione cream, azelaic acid, and a retinoid, and he was referred to his urologist for evaluation of finasteride discontinuation.Conclusion: These cases expand the limited literature on finasteride-associated melasma and highlight that improvement may require both discontinuation of the drug and targeted melasma therapy. Clinicians should consider 5-ARI exposure when evaluating new-onset or refractory facial hyperpigmentation, particularly in individuals with darker skin types, as early recognition and medication review may help mitigate persistent pigmentation.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"170-176"},"PeriodicalIF":0.8,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13030906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum. 勘误表。

IF 0.8

Case Reports in Dermatology Pub Date : 2026-02-11 eCollection Date: 2026-01-01 DOI: 10.1159/000550557

引用次数: 0